AstraZeneca investors react badly to CEO bonus payment plan

Nearly 40% of shareholders voted against the proposal to hand chief executive Pascal Soriot pay and perks of nearly €21m for 2021
Covid-19 vaccine developer AstraZeneca has suffered a substantial shareholder rebellion over proposals to hand its chief executive Pascal Soriot bigger bonus awards for the second consecutive year

Covid-19 vaccine developer AstraZeneca has suffered a substantial shareholder rebellion over proposals to hand its chief executive Pascal Soriot bigger bonus awards for the second consecutive year

Covid-19 vaccine developer AstraZeneca has suffered a substantial shareholder rebellion over proposals to hand its chief executive Pascal Soriot bigger bonus awards for the second consecutive year.

Nearly 40% voted against the policy, which could hand him pay and perks of nearly £18m (€21m) for 2021.

You have reached your article limit. Already a subscriber? Sign in

185 years of the Irish Examiner

185th
Anniversary Offer

Six months of digital access for €18.50

No obligation. Ts&Cs apply.

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited